On November 2, 2021 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, reported that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place on November 10-14, 2021 (Press release, Corvus Pharmaceuticals, NOV 2, 2021, View Source [SID1234594102]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The updated data from the mupadolimab study will be presented in a poster at SITC (Free SITC Whitepaper). Details of the poster presentation are as follows:
TITLE: Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)
PRESENTER: Jason J. Luke, M.D, University of Pittsburgh School of Medicine
CATEGORY: Immune-stimulants and immune modulators
POSTER #: 701
DATE & TIME: Friday, November 12, 2021, 7:00 a.m. – 8:30 p.m. ET
LOCATION: Walter E. Washington Convention Center, Hall E, or View Source
Conference Call, Webcast and Presentation Slides
Corvus will host a conference call and webcast on November 12, 2021 at 9:00 am ET (6:00 am PT) to discuss the update on mupadolimab and other topics. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) and using the conference ID 13724618. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.